Search

EHA’s advocacy for hematology continues

The EHA Board has recently approved five position papers which formulate EHA’s key lobbying priorities:

Support for hematology research in Horizon 2020 (and future EU research funding programs)
Access to treatment for patients with blood disorders
EU collaboration to reduce the prices…

Read more

EHA Statement on the Erasmus MC Attack

EHA is deeply saddened and appalled by the news of the twin shootings in Rotterdam, the Netherlands. We condemn these senseless acts of violence in the strongest possible terms.

Read more

Update on EU4Health Calls and Contracts for 2024

The European Health and Digital Executive Agency (HaDEA) has published the tentative calendar for the EU4Health program calls and contracts for 2024.

Read more

In Memoriam Anneke Brand

Picture: Ineke Oostveen

 

On Sunday, November 21, 2021, Anneke Brand, MD, PhD, emeritus professor at Leiden University Medical Center (LUMC), passed away suddenly. The European Hematology Association community is deeply saddened by Anneke’s passing.

Read more

SWG Educational Activities

Past EHA (HOPE) Asia 2021 meeting 10-11 September 2021, Virutal

Speakers
Laane - Systematic review of literature on multiple myeloma EHA evidence-based “Guidelines for the use of patient-reported outcomes in adult patients with hematological malignancies” in progress - Systematic review of literature…

Read more

SWG Educational Activities

EHA-SWG meetingsAn EMSCO meeting was held in October 2023 (Nice, France).

Read more

EHA-Baltic Hematology Tutorial on Lymphoid Malignancies, including Waldenström's Macroglobulinemia

EHA in close collaboration with the Estonian Society of Haematology, the Lithuanian Society of Hematology and the Latvian Hematology Society are organizing the first EHA-Baltic Hematology Tutorial on Lymphoid Malignancies, including Waldenström's Macroglobulinemia.

Read more

Professor Degos awarded at the 17th Congress of EHA in Amsterdam

Professor Degos has made a major contribution, to our understanding of the pathogenesis and treatment of acute promyelocytic leukemia (APL), to international public health and to the EHA.

Read more